How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Strabismus and Amblyopia Digital Therapeutics Market
- By Therapeutic Approach: Binocular Vision Therapy, Monocular Occlusion Therapy, Perceptual Learning Therapy, Virtual Reality Therapy, Pharmacological Digital Adjuncts
- By Device Platform: Mobile Applications (iOS/Android), PC-Based Software, Virtual Reality Headsets, Wearable Devices, Cloud-Based Platforms
- By Target Condition: Strabismus, Amblyopia, Concomitant Strabismus, Paralytic Strabismus, Refractive Amblyopia
- By End User: Pediatric Patients, Adult Patients, Orthoptists, Ophthalmologists, Vision Therapists
- By Distribution Channel: Direct to Consumer (DTC), Prescription-Based Distribution, Telemedicine Platforms, Healthcare Provider Networks
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Binocular Vision Therapy leads By Therapeutic Approach at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Strabismus and Amblyopia Digital Therapeutics Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Approach 5
Device Platform 5
Target Condition 5
End User 5
Distribution Channel 4
Companies profiled
Vivid Vision Inc.
NovaSight Ltd.
Binovi Technologies
Eyecarrot Innovations
NeuroVision Imaging
SightTech Global
Luminopia
OcuPrime Technologies
Neuroplasticity Labs
EyePlay Therapeutics
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Vivid Vision Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →NovaSight Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Binovi Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Eyecarrot Innovations
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →NeuroVision Imaging
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →SightTech Global
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Luminopia
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →OcuPrime Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Neuroplasticity Labs
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →EyePlay Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,590M by 2033 · 9.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Binocular Vision Therapy36.2
- Monocular Occlusion Therapy16.9
- Perceptual Learning Therapy9.2
- Virtual Reality Therapy18.7
- Pharmacological Digital Adjuncts19.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,252M → $2,515M · 9.1%
Europe$872.3M → $1,701M · 8.7%
Asia Pacific$796.4M → $1,513M · 8.3%
Latin America$493.0M → $936.1M · 8.3%
Middle East and Africa$379.3M → $767.1M · 9.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.012026
9.022027
9.042028
9.042029
9.062030
9.072031
9.092032
9.102033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Vivid Vision Inc.20.0
- NovaSight Ltd.10.6
- Binovi Technologies7.2
- Eyecarrot Innovations9.4
- NeuroVision Imaging10.2
- SightTech Global14.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Approach23.4%
Device Platform18.2%
Target Condition18.9%
End User25.8%
Distribution Channel13.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.8
- Europe22.9
- Asia Pacific20.4
- Latin America12.6
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Vivid Vision Inc. | 77 | 89 | 90 | 76 | 73 | 85 | 82 |
| NovaSight Ltd. | 88 | 74 | 85 | 87 | 87 | 91 | 85 |
| Binovi Technologies | 76 | 80 | 66 | 63 | 87 | 69 | 74 |
| Eyecarrot Innovations | 68 | 58 | 64 | 67 | 73 | 73 | 67 |
| NeuroVision Imaging | 52 | 65 | 52 | 77 | 59 | 64 | 62 |
| SightTech Global | 60 | 66 | 67 | 46 | 48 | 60 | 58 |
| Luminopia | 50 | 62 | 52 | 46 | 51 | 48 | 52 |
| OcuPrime Technologies | 46 | 50 | 58 | 59 | 45 | 46 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Vivid Vision Inc.
- NovaSight Ltd.
- Binovi Technologies
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Vivid Vision Inc. | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| NovaSight Ltd. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Binovi Technologies | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Eyecarrot Innovations | ◐ | ◐ | − | ◐ | − | ✓ |
| NeuroVision Imaging | ◐ | − | − | ◐ | ◐ | ✓ |
| SightTech Global | ◐ | ◐ | − | − | − | − |
| Luminopia | − | ◐ | ◐ | − | − | ◐ |
| OcuPrime Technologies | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1NovaSight Ltd.85
2Vivid Vision Inc.82
3Binovi Technologies74
4Eyecarrot Innovations67
5NeuroVision Imaging62
6SightTech Global58
7Luminopia52
8OcuPrime Technologies51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Vivid Vision Inc.NovaSight Ltd.
Challenger2
Strong scale, closing on the leaders.
Binovi TechnologiesEyecarrot Innovations
Contender2
Focused players with pockets of strength.
NeuroVision ImagingSightTech Global
Niche2
Specialists in a single segment or region.
LuminopiaOcuPrime Technologies
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Approach in North America, then scale across Strabismus and Amblyopia Digital Therapeutics Market — a $392M beachhead inside a $7.70B market.
Beachhead (SOM)$392Mobtainable near-term
Serviceable (SAM)$2.75Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Binocular Vision Therapy
Best fit — highest urgency & budget in Therapeutic Approach.
Economic buyer77 fit
Monocular Occlusion Therapy
Strong fit — clear ROI and a fast path to value.
End user66 fit
Perceptual Learning Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Approach in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Device Platform & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Target Condition
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Approach leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Strabismus and Amblyopia Digital Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation13%
Closed-won7%
$13.1KCAC
$64KLTV
4.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Strabismus and Amblyopia Digital Therapeutics Market is a resilient opportunity — $4.38B by 2033, compounding at 5.0%.
TAM · 2025$2.97Btoday
TAM · 2033$4.38Bforecast
CAGR5.0%2027–2033
Cumulative$32.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.38BTotal addressable market
SAM$1.58BServiceable available market
SOM$284MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.0% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Approach.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Approach moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.38BLarge & growingTAM by 2033 at 5.0% CAGR
$1.58BServiceable nowreachable with today’s model
$284MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.42BBear3.3% CAGR
$4.38BBase5.0% CAGR
$5.61BBull6.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Device Platform optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Strabismus and Amblyopia Digital Therapeutics Market — a $8.12B market by 2033. Plan: grow share from 11.2% to 18.6%.
Market size · 2033$8.12Btotal addressable
Market CAGR8.1%2027–2033
Target share18.6%from 11.2% today
Revenue ambition$1.51Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.2% | 18.6% | On track |
| Revenue | $912M | $1.51B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 34.5% | 38.9% | At risk |
| Customer retention | 85.7% | 96.3% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Approach
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Device Platform capability
A defensible second engine — invest in Device Platform to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Approach share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Device Platform
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $218M capacity & capability investment
- Greenlight bolt-on M&A in Device Platform
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Approach leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Strabismus and Amblyopia Digital Therapeutics Market conversation — a $11.4B market you can size, segment and defend in minutes.
Market size · 2033$11.4Btotal opportunity
Growth9.3%CAGR to 2033
Addressable buyers1,086+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Approach
Goal Grow share in Therapeutic Approach
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 2 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Vivid Vision Inc.NovaSight Ltd.Binovi TechnologiesEyecarrot InnovationsNeuroVision ImagingSightTech GlobalLuminopiaOcuPrime Technologies+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Strabismus and Amblyopia Digital Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Strabismus and Amblyopia Digital Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Storage Dewar and Dry Shipper Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportStop Smoking Hypnosis Software Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportStool Test Kit Market
Market size, share, segmentation and regional forecast.
$484M market · 2025 base year
View reportStool Specimen Container Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportStool Softener Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportStool Secretory Immunoglobulin A [SIgA] Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportStool Sample Container Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportStool DNA Isolation Kit Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportStool Collector Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportStool Biomarkers Test Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportStone Management Disposables Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportStone Management Devices Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.